Protara Therapeutics’ (TARA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a report published on Thursday morning, Benzinga reports. They currently have a $23.00 price objective on the stock. HC Wainwright also issued estimates for Protara Therapeutics’ Q3 2024 earnings at ($0.48) EPS, Q4 2024 earnings at ($0.51) EPS, FY2024 earnings at ($2.22) EPS, FY2025 earnings at ($2.67) EPS, FY2026 earnings at ($3.12) EPS, FY2027 earnings at ($3.14) EPS and FY2028 earnings at ($1.96) EPS.

Separately, Oppenheimer boosted their price objective on Protara Therapeutics from $26.00 to $30.00 and gave the stock an outperform rating in a research report on Monday, April 22nd.

Protara Therapeutics Price Performance

TARA stock remained flat at $1.90 during midday trading on Thursday. The company’s stock had a trading volume of 213,799 shares, compared to its average volume of 233,641. The stock has a market cap of $39.12 million, a price-to-earnings ratio of -0.51 and a beta of 1.85. The stock’s fifty day moving average price is $2.32 and its 200 day moving average price is $2.98. Protara Therapeutics has a 12 month low of $1.04 and a 12 month high of $5.24.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.37. As a group, analysts anticipate that Protara Therapeutics will post -3.56 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Opaleye Management Inc. sold 70,885 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $3.25, for a total transaction of $230,376.25. Following the completion of the sale, the insider now directly owns 126,050 shares in the company, valued at $409,662.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 248,588 shares of company stock worth $671,847. 12.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Protara Therapeutics

Institutional investors have recently bought and sold shares of the stock. Oppenheimer & Co. Inc. acquired a new stake in shares of Protara Therapeutics during the first quarter valued at approximately $40,000. Ikarian Capital LLC lifted its holdings in shares of Protara Therapeutics by 7.4% in the first quarter. Ikarian Capital LLC now owns 202,701 shares of the company’s stock valued at $813,000 after purchasing an additional 14,037 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Protara Therapeutics by 77.8% in the second quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock worth $313,000 after buying an additional 65,800 shares during the period. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.